COPD in SARS-CoV-2 pandemic. baseline characteristics related to hospital admissions

Expert Rev Respir Med. 2022 Apr;16(4):477-484. doi: 10.1080/17476348.2022.2031985. Epub 2022 Apr 6.

Abstract

Objective: To develop a predictive model for COPD patients admitted for COVID-19 to support clinical decision-making.

Method: Retrospective cohort study of 1313 COPD patients with microbiological confirmation of SARS-CoV-2 infection. The sample was randomly divided into two subsamples, for the purposes of derivation and validation of the prediction rule (60% and 40%,respectively). Data collected for this study included sociodemographic characteristics, baseline comorbidities, baseline treatments, and other background data. Multivariable logistic regression analysis was used to develop the predictive model.

Results: Male sex, older age, hospital admissions in the previous year, flu vaccination in the previous season, a Charlson Index>3 and a prescription of renin-angiotensin aldosterone system inhibitors at baseline were the main risk factors for hospital admission. The AUC of the categorized risk score was 0.72 and 0.69 in the derivation and validation samples, respectively. Based on the risk score, four groups were identified with a risk of hospital admission ranging from 21% to 80%.

Conclusions: We propose a classification system to identify COPD people with COVID-19 with a higher risk of hospitalization, and indirectly, more severe disease, that is easy to use in primary care, as well as hospital emergency room settings to help clinical decision-making.

Clinicaltrials.gov identifier: NCT04463706.

Keywords: COPD; SARS-COV-2; emergencies; hospital admission; primary health care; risk factors.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / epidemiology
  • Hospitalization
  • Hospitals
  • Humans
  • Male
  • Pandemics
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Pulmonary Disease, Chronic Obstructive* / epidemiology
  • Pulmonary Disease, Chronic Obstructive* / therapy
  • Retrospective Studies
  • SARS-CoV-2

Associated data

  • ClinicalTrials.gov/NCT04463706